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Serotonylation, the covalent linkage of serotonin to proteins has been discovered more
than 60 years ago but only recently the mechanisms and first functions have been
elucidated. It has been found that transglutaminases (TG) such as TG2 and the blood
coagulation factor XIIIa are the enzymes which catalyze the linkage of serotonin and
other monoamines to distinct glutamine (Gln) residues of target proteins. The first
target proteins, small G-proteins and extracellular matrix constituents, were found
in platelets and are pivotally involved in platelet aggregation and the formation of
thrombi. The serotonylation of the same proteins is also involved in insulin secretion
and in the proliferation of pulmonary vascular smooth muscle cells and thereby in the
pathogenesis of pulmonary arterial hypertension (PAH). Recently histones have been
described as targets of serotonylation opening the area of transcriptional control to this
posttranslational protein modification. Future studies will certainly reveal further target
proteins, signaling pathways, cellular processes, and diseases, in which serotonylation
or, more general, monoaminylation is important.
Keywords: serotonin, histone, G-protein, protein modification, pulmonary hypertension, epigenetics,
monoaminylation, transglutaminase
INTRODUCTION IN TRANSGLUTAMINATION
In the late 1950s the group of Waelsch et al. discovered that primary amines can be incorporated
into proteins by being covalently linked to glutamine (Gln) residues (Sarkar et al., 1957). These
included besides polyamines also monoamines such as serotonin, histamine and norepinephrine
(Clarke et al., 1959). This group also discovered the enzyme catalyzing this reaction and coined the
term transglutaminase for it (Mycek et al., 1959). However, the function of this posttranslational
modification of proteins remained unclear for more than 30 years. In the meantime at least 8
different transglutaminases (TG) were described, TG1-7 and blood coagulation factor XIII, and
it was shown that these enzymes also crosslink proteins by linking lysine residues of one protein to
glutamines of another (Lorand and Graham, 2003; Eckert et al., 2014; Lai et al., 2017). In contrast
to TGs, which are mainly intracellular, factor XIII is extracellular and needs to be activated to factor
XIIIa by thrombin during coagulation. TG can stiffen extracellular matrix by “gluing” proteins
together and therefore such enzymes are used in the food industry to process meat. The first hint on
the function of poly- or monoaminylation of proteins came from studies on bacterial toxins, such as
Bordetella toxin, which are also transglutaminases. Intracellularly, they transamidate polyamines to
small G-proteins and thereby modulate the immune response of the host (Aktories, 2011). In most
cases infectious agents hijack cellular processes and redirect them for their purpose. Thus when we
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looked for the mechanism by which serotonin regulates platelet
aggregation we considered that it could do this via the
mechanism the bacterial toxins exploited. Indeed, we discovered
that serotonin is covalently bound to small G-proteins in the
cytoplasm by the endogenous transglutaminase TG2 (Walther
et al., 2003). For this process we coined the term serotonylation
(Figure 1). Already one year earlier Dale et al. had discovered
that serotonin can be covalently linked to fibronectin and other
extracellular proteins of platelets by factor XIIIa, which generates
a particularly active form of thrombocytes, called coated platelets
(Dale et al., 2002; Dale, 2005).
TG2 is the most likely candidate for serotonylation in most
organs, since it is widely expressed in contrast to most other
members of the TG family (Lorand and Graham, 2003; Eckert
et al., 2014; Muma and Mi, 2015) and its reduction using siRNA
nearly completely inibited Rac1 serotonylation in neuronal cells
(Dai et al., 2008). Moreover TG1 and TG3 could not transamidate
small G-proteins (Vowinckel et al., 2012). However, other TGs
may anyhow contribute at least in some tissues since for example
in aortic smooth muscle cells the specific inhibitor for TG2,
Z-DON, reduced transamidation less efficiently than the general
TG inhibitor, cystamine (Johnson et al., 2012).
TG2 exhibits a very peculiar way of activation (Katt et al.,
2018). It has binding sites for the guanine nucleotides, GTP
or GDP, and for calcium which are mutually exclusive. At
normal intracellular concentrations of GTP or GDP TG2 remains
in a very compact and inactive configuration and only when
intracellular calcium concentrations rise e.g., elicited by the
activation of cell surface receptors the enzyme adopts the open
FIGURE 1 | Serotonylation. Serotonin is covalently linked to glutamine
residues in proteins by transglutaminases.
state and can transamidate substrates. It is not well understood
how substrate specificity and the selection of the modified Gln
residues is achieved. Accessibility of the Gln residue for the
enzyme active site seems to be a major determinant but a
specific serotonylation motif has not yet been defined (Lorand
and Graham, 2003; Lai et al., 2017).
METHODS TO DETECT
SEROTONYLATION
Direct Measurement of Serotonin
Dale et al. (2002) purified the serotonylated protein, in their
case fibrinogen, hydrolyzed the bond with serotonin using
mercaptoethane sulfonic acid and detected serotonin by HPLC.
This method however, only works when the protein is present in
high amounts and can be easily purified.
Radioactive Serotonin
The most obvious method to detect the covalent modification of
proteins by serotonin is the use of 3H- or 14C-labeled serotonin
(Walther et al., 2003; Paulmann et al., 2009; Hummerich et al.,
2012; Al-Zoairy et al., 2017; Farrelly et al., 2019). Measuring
radioactivity in protein precipitates or autoradiography of
protein gels reveals the incorporation of the monoamine in
certain proteins. However, this method is not very sensitive due
to the weak radioactivity of 3H and 14C.
Biotin-Labeled Serotonin
Other studies used biotinylated serotonin for transglutaminase
reactions (Watts et al., 2009). However, when biotin is linked
to the amino group of serotonin, TG can not anymore
use the adduct as substrate. Moreover the molecule gets
very large and can not enter cells anymore. Therefore
biorthogonal labeling was developed which used a small alkyne-
functionalized serotonin, which can be taken up in cells for the
transglutaminase reaction (Lin et al., 2013, 2014). Afterwards
a biotin-residue is specifically linked by click-chemistry to this
incorporated propargylated serotonin. The biotin-label then
allows purification and detection of the serotonylated protein on
Western blots and by mass spectrometry (Lin et al., 2013, 2014;
Farrelly et al., 2019).
Serotonin Antibodies
Antibodies against serotonin are produced by injection of
animals with conjugates of bovine serum albumin or other
proteins with serotonin. Therefore they are well-suited to detect
serotonin when it is bound to proteins and can be used in
Western blots and for immunoprecipitation (Guilluy et al., 2007,
2009; Dai et al., 2008; Paulmann et al., 2009; Watts et al., 2009;
Liu et al., 2011; Abdala-Valencia et al., 2012; Wang et al., 2012,
2016; Penumatsa K. et al., 2014; Penumatsa K. C. et al., 2014;
Penumatsa et al., 2017; Cui and Kaartinen, 2015; Ivashkin et al.,
2015, 2019; Al-Zoairy et al., 2017; Mi et al., 2017). The problem in
this case is cross reactivity with other non-serotonylated proteins
which can rarely be excluded with any antibody.
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Two-Dimensional Gel Electrophoresis
Guilluy et al. (2007) have used two-dimensional gel
electrophoresis to show that fibronectin changes its isoelectric
point when serotonylated. They proved the identity of the spot
by Western blot with an anti-serotonin antibody.
Serotonin as Competitor
Since it was technically difficult to detect protein-bound
serotonin some groups used mono-dansylcadaverine (MDC)
or 5-(biotinamido) pentylamine as transglutaminase substrates,
which can be easily detected in protein gels by fluorescence
or by anti-biotin antibodies, respectively (Hummerich and
Schloss, 2010; Cui and Kaartinen, 2015; Hummerich et al., 2015;
Farrelly et al., 2019). When the binding of these substrates
to proteins was inhibited by serotonin, they concluded that
serotonin can also be bound to the same proteins. However, this
method provides only indirect evidence and needs independent
verification. Furthermore, MDC is also often used as inhibitor
of transglutaminases.
Mass Spectrometry
The most reliable evidence for the existence of serotonylation
comes from mass spectrometry of proteins. By this method
peptide fragments of proteins were discovered which had
exactly the increase in molecular mass as predicted when
serotonin was attached to a Gln residue (Farrelly et al., 2019).
In most cases also the Gln residue could be distinguished.
For this method serotonylated peptides are enriched by
immunoprecipitation with serotonin-antibodies and therefore
quantitative measurements of serotonylation are hardly possible.
SUBSTRATES FOR SEROTONYLATION
Extracellular Proteins
The first described function of protein serotonylation concerned
extracellular proteins on hyper-stimulated platelets, in particular
fibrinogen, von Willebrand factor, and fibronectin (Dale et al.,
2002; Table 1). The covalently bound serotonin residues on these
proteins serves as glue to retain the proteins on the surface
of these so-called coated platelets (Dale, 2005). The authors
provided evidence that factor XIIIa is the main transglutaminase
involved, but also TG2 could not be excluded. Serotonylation
of fibronectin was later confirmed in a glial cell line by binding
of MDC which could be competed by serotonin (Hummerich
and Schloss, 2010) and by radioactive serotonin incorporation
(Hummerich et al., 2012). Serotonylation of fibronectin led to
an increased protein accumulation in the extracellular matrix of
these cells (Hummerich et al., 2012). Incorporation of propargyl
serotonin followed by mass spectrometry confirmed that Gln34,
Gln38 and Gln40 are serotonylated in fibronectin (Lin et al.,
2013) as had been shown when fibronectin was labeled with
MDC (Hoffmann et al., 2011). Interestingly already in 1976
fibronectin had been discovered as factor XIIIa substrate using
MDC (Mosher, 1976; Mosher et al., 1980).
In contrast, the serotonylation of fibronectin in osteoblasts
by factor XIIIa inhibits its crosslinking with other proteins
and thereby destabilizes the matrix and reduces mineralization
(Cui and Kaartinen, 2015).
The group of Fanburg has shown in several publications
that upregulated TG2 in pulmonary arterial hypertension (PAH)
serotonylates fibronectin in pulmonary arteries and thereby
contributes to the disease pathogenesis (Liu et al., 2011;
Penumatsa K. C. et al., 2014; Penumatsa and Fanburg, 2014;
Liu et al., 2011).
Small GTPases
When a certain Gln residue in small G-proteins [e.g., Gln61
in human Ras (Lin et al., 2013)] is serotonylated by TG2 the
protein gets constitutively active (Walther et al., 2003; Aktories,
2011). Since there is yet no reverse reaction known inactivation
can probably only be achieved by proteasomal degradation,
however, there are hints that this degradation gets accelerated
by serotonylation (Guilluy et al., 2007; Lin et al., 2013). We first
discovered the serotonylation of small G-proteins in platelets
where rab4 and rhoA serotonylation contributes to the effect of
serotonin on platelet aggregation (Walther et al., 2003; Table 1).
Serotonin has a dual role in platelets: it binds to 5-HT2A
receptors on the plasma membrane and increases intracellular
Ca2+ which activates TG2 and is taken up in the cytoplasm by
the serotonin transporter (SERT) serving as substrate for TG2-
mediated serotonylation. Serotonylation of small G-proteins
probably by TG2 is also involved in insulin secretion by
pancreatic beta cells. In these cells, serotonin promotes insulin
secretion by covalently modifying rab3a and rab27a, which are
essential small G-proteins in the secretory pathway of beta cells
(Paulmann et al., 2009). Accordingly, TG2 deficient mice are
glucose intolerant and show impaired insulin release (Bernassola
et al., 2002). Also insulin sensitivity in muscle seems to be
regulated by serotonin via serotonylation of small G-proteins.
TABLE 1 | List of serotonylated proteins.
Protein Cell type References
Fibronectin Platelets Dale et al., 2002
Vascular smooth muscle Penumatsa K. C. et al.,
2014
Glioma Hummerich and Schloss,
2010
Osteoblasts Cui and Kaartinen, 2015
Fibrinogen Platelets Dale et al., 2002
Glioma Hummerich et al., 2015
rab4, rhoA Platelets Walther et al., 2003
rhoA Vascular smooth muscle Guilluy et al., 2007; Wang
et al., 2012
rab3a, rab27a Pancreatic β-cells Paulmann et al., 2009
rab4 Skeletal muscle cells Al-Zoairy et al., 2017
rac1 Neurones Dai et al., 2008
ras Colorectal adenocarcinoma Lin et al., 2013
Histones Neurones Farrelly et al., 2019
Actins, myosins Vascular smooth muscle Watts et al., 2009
Akt Vascular smooth muscle Penumatsa K. et al., 2014
SERCA2a Cardiomyocytes Wang et al., 2016
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When L6 skeletal muscle cells are treated with serotonin, rab4
is serotonylated which leads to its activation and thereby to an
increased glucose uptake (Al-Zoairy et al., 2017). This effect can
be blocked by the TG2 inhibitor MDC.
The serotonin induced proliferative response of pulmonary
arterial smooth muscle cells, which is involved in the
pathogenesis of PAH is also mediated by the serotonylation
of the small G-protein, rhoA (Guilluy et al., 2007, 2009; Wang
et al., 2012). RhoA had already earlier been shown to be a
substrate of TG2 at Gln63 using MDC for transamidation
(Schmidt et al., 1998). Inhibition of serotonin uptake or of
TG2 inhibits rhoA serotonylation, and cellular proliferation
and contraction. Accordingly, blockers of TG2, SERT, and
rhoA ameliorate PAH development (Guilluy et al., 2009;
Wang et al., 2012, 2018).
In primary cortical neurons serotonin via 5-HT2A receptors
stimulates TG2 which serotonylates Rac1 and thereby regulates
spine density (Dai et al., 2008; Mi et al., 2017). Using
propargylated serotonin, Lin et al. (2013) showed that also Ras
gets serotonylated and thereby activated in different cell types.
Histones
Already in 1996 it had been described that histone 3 can
be modified with MDC at Gln5 by TG2 in vitro (Ballestar
et al., 1996). However, only recently it was shown that in vivo
serotonin is the amine covalently linked by TG2 to this residue
of histone H3, using propargylated and radioactive serotonin
as well as competition of MDC labeling by serotonin and mass
spectrometry (Farrelly et al., 2019; Table 1). While Ballestar et al.
(1996) had found also other histones in chicken nucleosomes
to be transamidated in vitro, Farrelly et al. (2019) could not
confirm these findings in human cells. Future studies need to
clarify whether other histones than H3 can be serotonylated
in certain species, cell types, or conditions. The serotonylation
of Gln5 in histone H3 does not interfere with trimethylation
on the neighboring Lys4 (H3K4me3) but exerts a permissive
transcriptional activity in neuronal cells in culture and in the
developing mouse brain. The reader for this novel histone
modification is still unknown but it could be shown that
the binding of the transcription factor TFIID to H3K4me3
bearing promoters and consequently transcription initiation gets
facilitated by it (Farrelly et al., 2019). Based on these findings
histone serotonylation became a novel epigenetic regulatory
mechanism (Anastas and Shi, 2019; Fu and Zhang, 2019; Zhao
et al., 2019; Zlotorynski, 2019). It remains to be established
whether some of the phenotypes observed in mice lacking
tryptophan hydroxylase 2 (TPH2) are depending on altered
epigenetic control of gene expression due to the lack of brain
serotonin (Alenina et al., 2009).
Other Proteins
The signaling protein Akt has been revealed as TG2 substrate for
serotonylation again in pulmonary arterial smooth muscle cells
(Penumatsa K. et al., 2014; Table 1). Since TG2 is upregulated
in these cells in PAH, Akt serotonylation may contribute to
pulmonary artery remodeling in this disease.
In isolated cardiomyocytes high concentrations of serotonin
induces the serotonylation of SERCA2a (Wang et al., 2016;
Table 1). The physiological consequences of this modification are
however, not clarified.
In cultured aortic smooth muscle cells contractile proteins
such as actins and myosins can get serotonylated and the
inhibition of TG2 by cystamine reduces serotonin induced
contraction of these cells (Watts et al., 2009; Table 1). However,
despite that mass spectrometry was performed the serotonylated
Gln residues in these proteins were not reported which would
have supported the specificity of the labeling method using
biotinylated serotonin. Notwithstandingly, at least some of
the discovered proteins, such as actin, were confirmed in
other studies using propargylated serotonin or MDC and
mass spectrometry in different cell types (Lin et al., 2014;
Hummerich et al., 2015).
In allergic lung inflammation, the serotonin precursor,
5-hydroxytryptophan ameliorates the symptoms in mice
and reduces the amount of serotonylated proteins in lung
endothelium, as well as in cultured pulmonary endothelial
cells (Abdala-Valencia et al., 2012). However, since anti-
serotonin antibodies were used in immunohistochemistry, the
serotonylated proteins were not identified.
Ivashkin et al. (2015, 2019) have published two studies in
which they used anti-serotonin antibodies to detect serotonylated
proteins in embryos of snails, sea urchins, mollusks, and
zebrafish. TG2 inhibition by cystamine diminished the signals.
In each case they found enrichment of these proteins in nuclei
and several bands on Western blots but they did not identify the
target proteins.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Compared to other covalent protein modifications, such
as phosphorylation, serotonylation has only quite recently
been discovered and not many functional consequences
of it have been described. Serotonin in the cytoplasm is
only available in a limited amount of cell types, which
either generate their own serotonin by expressing one of
the two tryptophan hydroxylases, TPH1 and TPH2, or
import it employing SERT or other less specific transporter
such as the Plasma Membrane Monoamine Transporter
(PMAT, SLC29A4), and the Organic Cation Transporters
OCT1 (SLC22A1), 2 (SLC22A2), or 3 (SLC22A3) (Walther
and Bader, 2003; Jonker and Schinkel, 2004; Daws, 2009).
Therefore serotonylation is expected not to occur in every
cell type. However, other monoamines such as histamine,
norepinephrine and dopamine are also substrates of TGs
and may replace serotonin in certain cell types by also being
used for “monoaminylation” (McConoughey et al., 2010;
Walther et al., 2011; Muma and Mi, 2015). This kind of protein
modification seem to be evolutionarily old, since it can be
found from snails to vertebrates (Ivashkin et al., 2015, 2019)
and uses a molecule, serotonin, which is present in nearly
all organisms on earth (Turlejski, 1996; Walther et al., 2011;
Csaba, 2015).
Still a lot of mechanistic questions remain open. Are all
TGs involved in monoaminylation or mainly TG2 and, for
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extracellular targets, factor XIIIa? How specific are TGs for
distinct Gln residues on selected target proteins and how is the
specificity brought about? Are there any cofactors involved which
confer specificity? Can TGs distinguish between monoamines
or is just the concentration in the cell decisive about which
monoamine is taken? In this respect, there are first data
that TG2 has different affinities for histamine, norepinephrine
and serotonin, serotonin being surprisingly the worst substrate
(Clarke et al., 1959; Lai and Greenberg, 2013). And finally is there
any enzymatic de-monoaminylation?
Despite the few examples of serotonylation which have been
discovered so far, it has already been implicated in important
physiological and pathophysiological processes. Probably it plays
a major role in transcriptional regulation during development in
several organisms by modulating histone-dependent epigenetic
effects (Ivashkin et al., 2015, 2019; Farrelly et al., 2019). Moreover
it contributes to the pathogenesis of PAH (Penumatsa and
Fanburg, 2014; Wang et al., 2018) and therefore serotonin may
be a valid therapeutic target for this disease (Matthes and Bader,
2018). Extracellular and intracellular serotonylation has been
found to be involved in platelet aggregation and insulin secretion
again offering therapeutic options (Walther et al., 2003; Dale,
2005; Paulmann et al., 2009). Since TG and serotonin have
numerous additional pathophysiologically relevant functions
(Berger et al., 2009; Daubert and Condron, 2010; McConoughey
et al., 2010; Eckert et al., 2014; Lai et al., 2017; Matthes and Bader,
2018), some of them may be dependent on each other and based
on serotonylation of yet unknown target proteins. Accordingly in
drosophila and mouse neurons an induced increase of serotonin
particularly in the cytoplasm leads to abnormalities reminiscent
of neurodegenerative disorders (Daubert and Condron, 2010).
In these models as well as in other comparable situations
in which cytoplasmatic or nuclear serotonin is increased the
signaling via serotonylation should be considered and may
offer novel mechanistic insights and therapeutic options for a
multitude of diseases.
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